RCS - Theracryf PLC - Ox-1 Investor Presentation

TheracryfAnnouncement

10/06/2025 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250610:nRSJ2328Ma&default-theme=true

RNS Number : 2328M  Theracryf PLC  10 June 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Ox-1 Investor Presentation

 

Alderley Park, 10 June 2025 - TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on neuropsychiatry and oncology, will be
hosting a webinar for investors at 11.30am BST, on Wednesday 11 June 2025.

 

It will provide an in-depth look at the Ox-1 addiction programme. The session
will be led by TheraCryf's CBO, Dr Helen Kuhlman, together with neuroscientist
and consultant to the Company, Dr Fraser Murray. Access to the session is open
to all existing and potential shareholders via the Investor Meet Company
platform.

 

Investors who already follow TheraCryf plc on the Investor Meet Company
platform have automatically been invited. New registrants can sign up to
Investor Meet Company for free HERE
(https://www.investormeetcompany.com/theracryf-plc/register-investor) .

 

-Ends-

Enquiries

 TheraCryf plc                                          +44 (0)1625 315 090

 Dr Huw Jones, CEO                                      enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Turner Pope Investments (Joint Broker)                 +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Cavendish Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

 Vigo Consulting                                        +44 (0)20 7390 0231

theracryf@vigoconsulting.com
 Rozi Morris

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma**
and neurodevelopmental disorders [**orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAFKEFDESEFA